Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Exp Cell Res. 2019 Feb 25;378(1):11–20. doi: 10.1016/j.yexcr.2019.01.026

Figure 1. TGFβ1 antagonizes BMP/Smad1/5 signaling.

Figure 1.

Primary sclerotome was treated with (A) vehicle control (−) or TGFβ1 (T) for 8hrs or (B) BMP4 (B) and BMP4 plus TGFβ1(B/T) for 24hrs. Relative pSmad1/5 levels were determined by Immunoblot assay. Bands on the blots were quantified by densitometry and pSmad1/5 levels were normalized to total Smad1 α-Tubulin was used as a protein loading control. One-way ANOVA was used for statistical analysis between independent samples. (n=3).